Navigation Links
Major New Review Supports the Broader Potential of CeNeS COMT,Inhibitor Discovery Programme

CAMBRIDGE, U.K. 2nd July 2007 - CeNeS Pharmaceuticals (AIM:CEN) ("CeNeS" or "the Company") the Cambridge-based biopharmaceutical company today announced that a paper published this week in CNS Drugs(1) further supports the hypothesis that a catechol-O-methyltransferase (COMT) inhibitor that acts in the brain would be a useful agent to address profound cognitive deficits in schizophrenia and bipolar disorder. CeNeS has an ongoing discovery programme to develop novel COMT inhibitors.

The paper reviews the preclinical and clinical data surrounding COMT and includes studies carried out by the world leading group based at the National Institute of Mental Health, Bethesda, Maryland, USA. The paper's authors collate recent developments in the analysis of the role of COMT genotypes and their involvement in cognitive deficits in schizophrenia and bipolar disorder. The paper supports the view that there is potential to use COMT inhibitors in ameliorating their cognitive deficits via an effect on prefrontal cortex brain function. As part of their conclusions the authors note, "The development of newer COMT inhibitors that can permeate the BBB (blood brain barrier) effectively and are devoid of serious adverse effects will allow expansion of the search for more specific, selective therapies for the treatment of cognitive disorders".

CeNeS has a leading position in the discovery of a novel series of COMT inhibitors with a programme currently focused on drugs for treatment of Parkinson's disease. In addition to this, the continuing progression of the scientific rationale for the potential use of COMT inhibitors in the treatment of schizophrenia and bipolar disorder places the CeNeS discovery programme in a good position in an exciting area of neuroscience.

Neil Clark, Chief Executive of CeNeS said: "CeNeS is excited about its discovery programme's potential to deliver improved drugs for the treatment of
'"/>




Page: 1 2 3 4

Related medicine technology :

1. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
2. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
3. Pooled Studies Showed Desvenlafaxine Succinate Significantly Improved Painful Symptoms and Anxious Symptoms Associated with Major Depressive Disorder in Adults, Compared With Placebo
4. Six-Week Investigational Study In Adults With Major Depressive Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole Therapy With Antidepressants
5. Major Manufacturer of Unapproved and Adulterated Drugs
6. Exforge Helps Vast Majority of Patients Effectively Control Their Blood Pressure After Failing on Other Medicines, According to New Clinical Data
7. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
8. Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference
9. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
10. New Clinical Data for Cytogens Quadramet and Prostacint to be Reported at Upcoming Major Medical Meetings
11. Major Discovery Raises Prospect of Better Patient Care By Improving Platelet Life Span

Post Your Comments:
(Date:11/7/2009)...a., Nov. 7 Patients reported C1-es...ive therapy in treating acute swelling attacks at ...tic disorder, according to data presented today at...; Immunology (ACAAI) Annual Meeting. The results c...ted in parallel with the ongoing, prospective, ope...
(Date:11/6/2009)...ov. 6 Oxygen Biotherapeu...ced that a previously approved reverse split of it...ading on Monday, Nov. 9, 2009 on a 1-for-15 split-...s will trade under the new symbol OXBT. The stock ...en the split becomes effective. ,, "This revers...
(Date:11/6/2009)...s., Nov. 6 DUSA Pharmace...logy company that is developing and marketing Levu...roducts focused on patients with common skin condi...ef Executive Officer, will present a corporate ove...2009 on Tuesday, November 10, 2009 at 10:00 a.m. E...
Breaking Medicine Technology:Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care 2Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care 3Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009 2Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009 3Spain 26apos 3Bs Health Ministry Contracts Authenware to Fortify System Security Prior to Flu Season 14297 1Spain 26apos 3Bs Health Ministry Contracts Authenware to Fortify System Security Prior to Flu Season 14297 2Spain 26apos 3Bs Health Ministry Contracts Authenware to Fortify System Security Prior to Flu Season 14297 3Prodigy Diabetes Care LLC Expands Global Reach to European Diabetes Patients 58540 1Prodigy Diabetes Care LLC Expands Global Reach to European Diabetes Patients 58540 2Blythe Danner and Gwyneth Paltrow Ask Americans to Volunteer for Healthier Life in New Public Service Announcement 58538 1Blythe Danner and Gwyneth Paltrow Ask Americans to Volunteer for Healthier Life in New Public Service Announcement 58538 2Blythe Danner and Gwyneth Paltrow Ask Americans to Volunteer for Healthier Life in New Public Service Announcement 58538 3
... DIEGO, March 20 Valor Medical, an emerging medic...y that the first human,implant of Neucrylate AN fo... Dr. Sean Pakbaz at the University of Tehran. The ...tocol that had been approved by the University,s,I... the patient,s aneurysm was a type and location,th...
...ision makes convenient self-testing a financial re...ion patients, INDIANAPOLIS, March 19 Medicare Pa...uipment and supplies for all long-term,warfarin us...h a portable,handheld meter. The change opens the ...complications for a broader spectrum of anticoagul...
Other Medicine Technology:Medicare Announces Expanded Coverage for Warfarin Patients Monitoring Clotting Time at Home 2Medicare Announces Expanded Coverage for Warfarin Patients Monitoring Clotting Time at Home 3Medicare Announces Expanded Coverage for Warfarin Patients Monitoring Clotting Time at Home 4
(Date:11/7/2009)...USTON, Nov. 7 Members o...duce an emergency resolution rescinding the AMA,s ...icians that they are responsible to their PATIENTS...kes, Director of Policy for the Association of Ame...ine, a coalition of other medical groups. ,, "...
(Date:11/7/2009)...Brown: "Faithful Catholics have a responsibility t...gotiate the status quo." ,, WASHINGTON, Nov. ...ue president Judie Brown released the following st...ll support Speaker Nancy Pelosi,s Affordable Healt...endment preserving the status quo for abortion is ...
(Date:11/7/2009)...SHINGTON, Nov. 7 Speake... availability this afternoon following a Democrati...Caucus Room. Below are the Speaker,s opening rema...it was a great occasion for us to receive the Pres...l be making history with our vote and making progr...
(Date:11/7/2009)...O, Nov. 7 The Public Relations Society of America...low on Diane Gage Lofgren, senior vice president o... Permanente, tonight at a ceremony at PRSA,s 2009 ... inducted into the PRSA College of Fellows is one ...id Michael Herman, APR, SAGE, Fellow PRSA, and 200...
(Date:11/7/2009)...ight back to stem a growing problem across the U.S... Nearly half of students at four-year colleges do ...inge drinking -- downing five or more alcoholic dr...tifying alcohol as a drug," said Jenny Hwang, asso...ing center at Stony Brook University on Long Islan...
Breaking Medicine News(10 mins):Health News:Statement Regarding Cardinal Rigali's Memo Protecting the 'Status Quo' On Life 2Health News:Pelosi Remarks Following House Democrats' Meeting with President Obama 2Health News:PRSA Inducts Head of Public Relations for Kaiser Permanente Into the College of Fellows for Contributions to the Profession and Lifetime Achievement 2Health News:PRSA Inducts Head of Public Relations for Kaiser Permanente Into the College of Fellows for Contributions to the Profession and Lifetime Achievement 3Health News:Binge Drinking Puts the Brain, and Life Itself, at Risk 2Health News:Binge Drinking Puts the Brain, and Life Itself, at Risk 3
... dose-response effect on mortality from alcohol-re...e type of alcoholic beverage, was more significant...am led by by Professor You-Ming Li from Zhejiang U...isk threshold of daily alcohol intake and the dura...
...ce and calm, according to a new study from the Pop... at Austin. Starting at about age 60, participants...an their younger counterparts. , Catherine Ross a...dicine. The research was funded in part by the Nat...
...an 20% over the next five years, a...ass., May 20 According to Millennium Research,Gro...es 2008 report, the,thoracic aortic stent graft ma... expansion in this area is dependent,on positive c...
...Growth, FORT LAUDERDALE, Fla., May 20 Best Pract...ider of underwriting, medical risk,management, cla...,announced the appointment of G. Scott Cantini to ...r. Riley are charged,with driving the leadership a...
...te in key organs , , TUESDAY, May 20 (Heal...y also protect against adenovirus, which causes up...viruses that causes the common cold. , Currently, ...mething that needs to be done before new drugs can...
...irstCall/ -- Tianyin,Pharmaceutical, Co., Inc., (O...ier of modernized traditional Chinese medicine ("T... it signed over 60 new distribution,agreements wit...one year, were signed,with several of the Company,...
Other Medicine News:Health News:With age comes a sense of peace and calm 2Health News:High Growth Potential for Carotid Stent and Thoracic Aortic Stent Graft Markets 2Health News:High Growth Potential for Carotid Stent and Thoracic Aortic Stent Graft Markets 3Health News:Best Practices Insurance Services Announces Key Additions to Senior Management 2Health News:Smallpox Drug May Protect Against Common Cold 2Health News:Tianyin Pharmaceutical Signs Over 60 New Distribution Agreements with 15 Regional Distributors 2Health News:Tianyin Pharmaceutical Signs Over 60 New Distribution Agreements with 15 Regional Distributors 3
Zebra 140xiIII Barcode Printer
...use technology that improves patient outcomes. Rig...o-use BD.id Patient Identification System for Spec..., the patient, the specimen container, and the ord...able labels only for specimens actually collected,...
...cation and laboratory specimen labeling system use...ist or nurse, the identity of the patient and the ...e, a bar coded sample ID label is printed right at...minates the interface problems inherent with other...
...ns, a Cerner point-of-care solution, is a bar-code...llection. The solution enhances the safety and acc...ying bar-code scanning technology, wireless networ...prevent potential patient identification and speci...
Medicine Products: